60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs

• Jay Milo,
• Stephanie Hund,
• Angeliki Apostolaki,
• Siena Tabuena-Frolli,
• Karina Kulangara,
• Francisco Ponce,
• Lindsay Peltz,
• Chris La Placa,
• Monika Vilardo,
• Brittany Watts,
• Grant Toland,
• Alex Posch

Affiliations

Jay Milo

1Agilent, Carpinteria, CA, USA

Stephanie Hund

1Agilent, Carpinteria, CA, USA

Angeliki Apostolaki

1Agilent, Carpinteria, CA, USA

Siena Tabuena-Frolli

1Agilent, Carpinteria, CA, USA

Karina Kulangara

1Agilent, Carpinteria, CA, USA

Francisco Ponce

Agilent Technologies, Carpinteria, CA, USA

Lindsay Peltz

Agilent Technologies, Carpinteria, CA, USA

Chris La Placa

Agilent Technologies, Carpinteria, CA, USA

Monika Vilardo

Agilent Technologies, Carpinteria, CA, USA

Brittany Watts

Agilent Technologies, Carpinteria, CA, USA

Grant Toland

Agilent Technologies, Carpinteria, CA, USA

Alex Posch

Agilent Technologies, Carpinteria, CA, USA